预防性使用甲氧苄啶-磺胺甲噁唑对中性粒细胞胞质抗体相关性血管炎严重感染发生率的时变效应:一项目标试验模拟研究
这项多中心队列研究模拟目标试验,纳入296例接受利妥昔单抗或环磷酰胺诱导治疗的中性粒细胞胞质抗体相关性血管炎患者,比较诱导治疗后14天内使用与未使用甲氧苄啶-磺胺甲噁唑预防的严重感染发生率。预防组严重感染发生率显著低于对照组(HR 0.48),但获益仅限于前180天(HR 0.41),此后无显著差异。
要点
- 预防性TMP-SMX使严重感染风险显著降低(HR 0.48,95%CI 0.32-0.72)。
- 获益仅见于前180天(HR 0.41),之后无显著差异(HR 3.67,交互P=0.044)。
- 预防1例严重感染需治疗8.0例,1例严重药物不良反应致伤害需127.4例。
核心结论
- 预防性TMP-SMX显著降低接受利妥昔单抗或环磷酰胺诱导治疗的AAV患者严重感染风险,尤其在前6个月。
研究设计与样本
- 多中心队列研究,模拟目标试验,纳入296例接受利妥昔单抗或环磷酰胺诱导治疗的AAV患者。
- 按诱导治疗后14天内是否使用TMP-SMX分为预防组240例和对照组56例(意向性治疗),并作为时变暴露分析。
- 采用逆概率加权最小化两组基线不平衡,主要结局为1年严重感染发生率。
主要发现
- 观察252.1人年期间,65例患者共记录77例严重感染,病死率18.5%。
- 多数严重感染(66例,85.7%)发生于观察前180天内。
- 预防组严重感染发生率显著低于对照组(HR 0.48,95%CI 0.32-0.72)。
- TMP-SMX获益仅在前180天显著(HR 0.41,95%CI 0.22-0.76),此后无显著差异(HR 3.67,95%CI 0.46-29.43),交互P=0.044。
- 时变分析结果与上述一致,基于1例TMP-SMX相关严重药物不良反应,致伤害需治疗人数为127.4,预防1例严重感染需治疗人数为8.0。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to investigate the effect of prophylactic trimethoprim-sulfamethoxazole (TMP-SMX) on the incidence of serious infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). METHODS: This multicenter cohort study was designed to emulate a target trial that studied 296 patients with AAV who were treated with rituximab (RTX) or cyclophosphamide (CYC) as induction therapy. Patients were grouped based on the administration of TMP-SMX within 14 days following induction therapy (n = 240 and 56 patients in prophylaxis and control groups, respectively) (intention-to-treat) and also as a time-dependent exposure (time-varying). Inverse probability weighting was applied to minimize the baseline imbalance between the two groups. The primary outcome was one-year incidence of serious infection. RESULTS: During the 252.1 person-years of observation, 77 cases of serious infections were recorded in 65 patients with a fatality rate of 18.5%. Most serious infections (n = 66, 85.7%) occurred within the first 180 days of observation. The prophylaxis group showed a significantly lower incidence of serious infections than the control group (hazard ratio [HR] 0.48 [95% confidence interval (CI) 0.32-0.72]). However, this beneficial effect of TMP-SMX was only significant during the first 180 days (HR 0.41 [95% CI 0.22-0.76]) and not thereafter (HR 3.67 [95% CI 0.46-29.43]) (interaction P = 0.044). This result was also consistent with the time-varying analysis result. Based on one case of severe adverse drug reaction related to TMP-SMX, the number needed to harm was 127.4, whereas the number needed to treat to prevent one serious infection was 8.0. CONCLUSION: Prophylactic TMP-SMX significantly reduced the risk of serious infections in patients with AAV, particularly during the first six months of induction therapy with RTX or CYC.
引用
- Kim YK, Curtis JR, Choi SR, et al. Time-Dependent Effect of Prophylactic Trimethoprim-Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Target Trial Emulation Study. Arthritis Rheumatol. 2025. PMID: 40229227. doi:10.1002/art.43185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。